This week Destiny Pharma announced the appointment of a new CEO, Chris Tovey, and he comes with a very impressive track record.
In this video I look at Chris’s career & why he would be attracted to Destiny Pharma.
Destiny Pharma is a clinical phase biotechnology company dedicated to infection prevention. The company has two late stage clinical programmes and an earlier preclinical pipeline. The strategy is to build strong clinical data packages and then seek partners for the final clinical studies and commercialisation.
Three seperate brokers have a target, the average of which is 860% above the current share price and this is less than half the potential if you take into account their other late stage asset and earlier pipeline.